伊拉非布拉诺 PPARα/δ 双重激素 改善卵胺诱导过敏喘
1Department of Fundamental Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02446, Republic of Korea.
Biomolecules & therapeutics
|June 5, 2024
概括
作为PPARα/δ双重激动剂的埃拉非布拉诺,通过抑制炎症和气道过敏反应,有效地减少了小鼠的过敏喘症状. 这项研究突出了elafibranor.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 喘涉及慢性呼吸道炎症和重塑.
- 过氧体增殖器激活受体 (PPARs) 调节炎症过程.
- 在喘中研究了PPARγ激动剂,但对PPARα/δ的作用不太了解.
研究的目的:
- 为了研究elafibranor,一个PPARα/δ双重激动剂,作为一种潜在的治疗过敏性喘.
- 评估elafibranor对卵蛋白 (OVA) 诱导的喘模型的影响.
- 为了评估elafibranor对杆细胞脱粒和体内喘病理学的影响.
主要方法:
- 在实验室中对elafibranor对RBL-2H3巨细胞脱粒的评估.
- 在体内研究,使用OVA诱导过敏喘的小鼠模型.
- 支气管支气管洗液 (BALF) 对免疫细胞,细胞因子 (IL-13) 和免疫球蛋白E (IgE) 的分析.
- 对肺组织进行组织学检查,以检查炎症和粘素的产生.
主要成果:
- 伊拉非布拉诺抑制了抗原诱导的巨细胞脱粒化,没有细胞毒性.
- 埃拉非布拉诺 (10毫克/公斤) 抑制了小鼠的OVA诱导的气道过敏反应.
- 在BALF.中减少免疫细胞透和促炎性细胞因子水平 (IL-13) .
- 由OVA诱导的血清IgE水平降低和肺炎,包括粘素过度产生.
结论:
- 在临床前模型中,Elafibranor显示出显著的抗炎和抗喘特性.
- PPARα/δ激应是一种对过敏性喘有前途的治疗途径.
- 埃拉非布拉诺需要进一步研究,作为对过敏性喘患者的潜在治疗方法.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
276
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
276
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
271
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
271
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
249
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
249
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
727
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
727
01:30Adrenergic Agonists: Direct-Acting Agents
1.4K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.4K